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Background: The aim of our meta-analysis is to assess the efficacy and safety of the target combined
chemotherapy for the patients with unresectable advanced or recurrent gastric cancer.
Methods: In accordance with the standard meta-analysis procedures, the patients included in our study were with
unresectable advanced or recurrent gastric cancer and allocated randomly to receive target combined chemotherapy
or the traditional chemotherapy. The search was applied to PubMed, EMBASE, Science Citation Index Expanded,
Cocran’s library (from inception to February 2016). All analyses were performed by STATA 12.0, with the odds ratio,
hazard ratio, and 95 % confidence interval as the effect measures.
Results: Fourteen studies were included in this meta-analysis. A total of 5067 patients with advanced gastric cancer
were divided into two arms: traditional chemotherapy arm and target combined chemotherapy arm. A significant
improvement for overall survival (hazard ratio was 0.89, 95 % confidence interval: 0.83–0.95) and overall response rate
(odds ratio was 1.44, 95 % confidence interval: 1.15–1.81) was observed, but no significant difference was found
for progression-free survival (hazard ratio was 0.89, 95 % confidence interval: 0.77–1.00) in the target combined
chemotherapy arm. In subgroup analysis, increasing benefits regarding overall survival and progression-free
survival were found in anti epidermal growth factor receptor target drugs for selected patients subgroup and
anti vascular endothelial growth factor receptor target drugs for unselected patients subgroup, but not in anti
epidermal growth factor receptor target drugs for unselected patients subgroup. Besides, some adverse events
were increased in the target combined chemotherapy arm.
Conclusions: The target combined chemotherapy represented a better overall survival benefit and treatment
efficiency and higher incidence of some grade 3–4 adverse events than the traditional chemotherapy for patients
with unresectable advanced or recurrence gastric cancer. The anti vascular endothelial growth factor receptor
drugs can improve the efficacy in the whole patients with unresectable advanced or recurrence gastric cancer
and the anti epidermal growth factor receptor target drugs can only improve the efficacy in the epidermal
growth factor receptor positive patients.
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Gastric cancer is the fifth most common malignant neo-
plasm and the third leading cause of death related to cancer
[1]. Surgery remains the only potentially curative treatment
in early stage adenocarcinoma, and multidisciplinary treat-
ment has improved the prognosis in radically resectable
disease [2]. However, most of patients show an advanced
disease or distant metastasis at diagnosis and lose the op-
portunity of surgical treatment. At the same time, most of
the patients relapsed after a prior curative surgical ap-
proach. The prognosis is very poor in these patients and
chemotherapy represents the reference treatment deter-
mining a significantly higher survival benefit compared
with the best supportive care alone [3]. However, despite
the use of the latest chemotherapy regimen, the median
survival time of patients with advanced gastric cancer was
only about 10 months [4]. Therefore, it is important to
change the existing strategies and find more effective com-
bination chemotherapy for the advanced gastric cancer.
In order to improve the effectiveness of treatment for
patients with advanced gastric cancer, scores of efforts
has been made. In recent years, with the tumor molecular
biology, genetic mechanism and epigenetic association
studies gradually expanded, more and more target drugs
have been used on the treatment of advanced gastric can-
cer. As the important signaling pathway of tumor growth
and progression, epidermal growth factor receptor (EGFR)
and vascular endothelial growth factor receptor (VEGFR)
are closely related to tumor invasiveness, studies have
confirmed that the expression of EGFR and VEGFR
was related to the poor prognosis of gastric cancer [5, 6].
Therefore, anti-EGFR and anti-VEGFR target drugs for
the treatment of advanced gastric cancer may be of great
significance. Trastuzumab was the first molecule-targeted
agent approved for the treatment of gastric cancer after
the randomized, prospective, multicenter, phase 3 (ToGA)
study. The ToGA study demonstrated that anti-EGFR tar-
get drugs (trastuzumab) combined chemotherapy achieved
a significant survival benefit compared with the traditional
chemotherapy [7]. Subsequently, more anti-EGFR and
anti-VEGFR target drugs were used for the treatment of
advanced gastric cancer. According to the good survival
benefit of the TOGA [7] and RAINBOW [8] clinical trials,
the NCCN (National Comprehensive Cancer Network)
guidelines for gastric cancer in year 2015 recommends
truastuzumab can be used as first-line chemotherapy for
patients with human epidermal growth factor receptor-2
positive advanced gastric cancer, and points out that
ramucirumab can be used for advanced gastric cancer
patients after the failure of first-line chemotherapy. On
the other hand, some other clinical trials [9–13]
showed that target combined chemotherapy did not
achieve any significant survival benefit compared to the
traditional. Currently, the efficacy and safety of targetdrug for the treatment of advanced gastric cancer re-
mains controversial.
At present, along with the development of evidence-
based medicine, world medical researchers generally
accept the large scale, multicenter randomized clinical
trials (RCTs) and the combination of meta-analysis as
the best evidence. Therefore, we made a summary of the
studies about the treatment of the target drugs for ad-
vanced gastric cancer, and carried out a meta-analysis in




According to the relevant requirements of Cochrane col-
laboration network and the proposed search strategy,
two authors used a broad search strategy independently
with key words “gastric cancer”, “target” and “chemo-
therapy” in PubMed, EMBASE, Science Citation Index
Expanded, Cocran’s library (from inception to February
2016). An additional search through Google Scholar and
the clinical trials registration website was conducted to
obtain information about the registered trails. Discrep-
ancies were resolved by the third author. In order to en-
sure the integrity of the retrieval, we also conducted a
manual search.
Inclusion and exclusion criteria
Patients with gastric cancer involved in the studies were:
(1) Confirmed by endoscopic biopsy and postoperative
pathological examination; (2) No other primary tumor
treatment history; (3) No significant difference of basic
information was existed between patients when random
assigned; (4) No obvious chemotherapy taboo and liver
and kidney dysfunction; (5) Performance status (PS)≦2.
The inclusion criteria were as follows: (1) studies aimed
to compare efficacy or safety between target combined
chemotherapy and the traditional chemotherapy as the
treatment for patients with advanced gastric adenocarcin-
oma (unresectable, recurrent or metastatic gastric cancer);
(2) data for calculating the efficacy or safety of these two
therapies were enough. The sufficient data to calculate a
hazard ratio (HR) and 95 % confidence interval (95 % CI)
for overall survival (OS) and progression-free survival
(PFS) and a odds ratio (OR) with 95 % CI for overall re-
sponse rate (ORR) and adverse events should be available;
(3) randomized controlled trials of II phase and III phase;
(4) more than 20 patients involved in the trails; (5) articles
published in English language; (6) Similar studies or the
same research retrieved the recently published article.
The exclusion criteria were: (1) studies with insuffi-
ciently data for efficacy and safety including protocols and
phase I clinical trials; (2) studies based on overlapping pa-
tients; (3) meta-analysis, cohort study, review, single test,
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the expert experience; (4) outcome was unclear or the ap-
parent paradox existed; (5) after contacting the original
author or magazine, it still cannot get enough data; (6) tar-
get drugs monopoly or different target drugs combined
chemotherapy; (7) articles published in non-English
language books or papers or the publication of the lack
of credibility.
Data extraction and outcomes
Data retrieved from the publications included: author’s
name, year of publication, treatment, number of patients,
age, sex, liver function, kidney function, genes that drugs
targeted, country (or area) of patients etc. Primary out-
comes were overall survival, progression-free survival and
overall response rate. Secondary outcomes were adverse
events. All data was extracted independently by two in-
vestigators, and any discrepancy between the reviewers
was resolved by consensus. As all tudies were random-
ized controlled trials, we summarized the basic infor-
mation and scored the studies, according to the
Cochrane manual scoring standard. This article followed
the QUORUM and the Cochrane Collaboration guidelines
(http://www.cochrane.de) for reporting meta-analysis
(PRISMA statement).
Statistical analysis
All data in our meta-analysis were analysed by using the
STATA 12.0 package (StataCorp, College Station, TX,
USA). HR with 95 % CI was used for PFS and OS as
demonstrated by Parmar MK et al. and HR > 1 reflects
more deaths or progression in the target combined
chemotherapy arm [14]. For binary data, including ORR
and adverse events, OR with 95 % CI was used and a
benefit outcome for chemotherapy response or an un-
favorable outcome for adverse events was found in the
target combined chemotherapy arm when OR > 1. Het-
erogeneity was assessed by I2 inconsistency test and
χ2-based Cocran’s Q statistic test in which I2 > 50 %, or
P < 0.05 indicated significant heterogeneity. All studies
included in this paper are randomized controlled tri-
als, so when I2 < 50 %, the fixed effect model was used,
or the random effects model conversely. The subgroup
analysis was performed when necessary (such as large
heterogeneity, I2 > 50 %). Publication bias was detected




According to the retrieval method mentioned above, 1086
potentially relevant studies were assessed. Detailed steps
of search are shown in Fig. 1. After the selection proced-
ure, fourteen studies were included [7–10, 12, 13, 15–22],with a total of 5067 patients with advanced gastric cancer
(2539 patients in the target combined chemotherapy arm
and 2528 patients in the traditional chemotherapy arm).
There was no significant difference in the baselines (such
as age, gender, tumor location, PS score, country, etc.).
The basic characteristics of these studies were showed in
Table 1. For the retrieved fourteen studies, ten were for
the first-line chemotherapy and four were for the second-
line chemotherapy. In terms of the patient’s status, ten
studies were designed for the unselected (whole) advanced
gastric cancer patients and four studies were for the se-
lected (EGFR-positive). And we also noted that patients in
seven studies came from Asia, two from Europe, four from
worldwide, while one’s information is unknown [15]. As to
the difference of the target drugs, eight studies used the
anti-EGFR target drugs and the six remaining studies used
the anti-VEGFR target drugs. All of the included studies
were of high quality (Table 2).
Progression-free survival (PFS)
Data on progression-free survival was available in thir-
teen studies (4962 patients), there was an significant het-
erogeneity for PFS between these studies when pooling
the HR. Then we pooled the HR in random-model and
found no significant improvement for PFS (HR = 0.89,
95 % CI: 0.77–1.00, P = 0.055; I2 = 68.2 %). Depending on
the difference of the target drugs and patient’s status
that whether they were selected or not, when entering
the studies, the studies were divided to three subgroups.
The pooled HR was 0.80 (95 % CI: 0.65–0.95, P = 0.009)
in anti-VEGFR target drugs for unselected patients sub-
group, 1.12 (95 % CI: 0.92–1.32, P = 0.228) in anti-EGFR
target drugs for unselected patients subgroup, 0.77
(95 % CI: 0.68–0.87, P < 0.001) in anti-EGFR target drugs
for selected (EGFR-positive) patients subgroup (Fig. 2).
A significant improvement for PFS was found in anti-
VEGFR target drugs for unselected and anti-EGFR target
drugs for selected patient subgroup, not in anti-EGFR
target drugs for unselected patient subgroup.
Overall survival (OS)
All the fourteen studies demonstrated OS. The I2 value
of heterogeneity test was 35.4 % and a fixed-effect model
was used. The pooled HR was 0.89 (95 % CI: 0.83–0.95,
P = 0.001). The difference had statistically significance.
There was an significant benefit and a risk reduction of
death by 11 % (HR = 0.89) in target combined chemo-
therapy arm, compared to the traditional chemotherapy
arm. As to subgroup analysis, a significant improvement
for OS was found in anti-VEGFR target drugs for unse-
lected patients subgroup (HR = 0.86, 95 % CI: 0.77–0.95,
P = 0.003), and anti-EGFR target drugs for selected patients
subgroup (HR = 0.82, 95 % CI: 0.72–0.93, P = 0.001). But
there was no significant improvement for OS in anti-EGFR
Fig. 1 Meta-analysis profile summarizing trail flow
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95 % CI: 0.93–1.20, P = 0.342) (Fig. 3).
Overall response rate (ORR)
All the fourteen studies demonstrated ORR. The ORR of
the target combined chemotherapy arm ranged from
17.5 % to 62.2 %, while the ORR of traditional chemo-
therapy arm ranged from 8.5 % to 58.3 %. The I2 value
of heterogeneity test was 63.8 % and a random-effect
model was used. The meta-analysis shown an significant
improvement for ORR in target combined chemotherapy
arm (OR = 1.44, 95 % CI: 1.15–1.81, P = 0.002). Similarly,
a significant improvement for ORR was found in anti-
VEGFR target drugs for unselected patients subgroup
(OR = 1.54, 95 % CI: 1.14–2.08, P = 0.005). But, consist-
ent result was found between two arms in the subgroups
of anti-EGFR target drugs for selected patients subgroup
(OR = 1.09, 95 % CI: 0.88–1.35, P = 0.433) and anti-
EGFR target drugs for unselected patients subgroup
(OR = 1.55, 95 % CI: 0.87–2.78, P = 0.140) (Fig. 4).
Grade 3 to 4 adverse events
Due to the difference of the adverse events reported in
the studies, we summarized the grade 3–4 adverse events
that at least reported in five trials and the results were
showed in Table 3. For the whole adverse events of 3–4grade, data was available in six of the trials and the pooled
OR was 1.53 (95 % CI: 0.98–2.40, P = 0.062). There was no
significant difference in the incidence of the whole grade
3–4 adverse events between two arms. Similarly, there was
no difference in the grade 3 to 4 hematological adverse
events (such as Anemia, Thrombocytopenia, neutropenia,
leucopenia). Only constipation was decreased in the target
combined chemotherapy arm and diarrhea, fatigue, the
skin and subcutaneous tissue disorders (rash, hand-foot
syndrome, stomatitis) shown a significant difference be-
tween two arms.
Publication bias
Publication bias was detected by Begg’s test and Egger’s
test. P < 0.05 confirmed the existence of publication bias.
No publication bias was shown in OS (Begg’s P = 0.324,
Egger’s P = 0.279) and ORR (Begg’s P = 0.827, Egger’s
P = 0.936). PFS showed borderline publication bias by
Begg’s test (P = 0.044), however, no publication bias by
Egger’s test (P = 0.108).
Discussion
Systematic chemotherapy is the basic treatment for pa-
tients with advanced gastric cancer, and it can achieve
better survival benefits compared with single drug
chemotherapy or best supportive care [3]. But, for the
Table 1 Basic characteristics of the studies included in this meta-analysis
Study Regimen PN Area TP TG Patient
Bang Y. J 2010 [7] Trastuzumab + fluoropyrimidine + cisplatin 294 worldwide FL EGFR Selected
fluoropyrimidine-cisplatin 290
Wilke H 2014 [8] Ramucirumab + paclitaxel 330 Asia SL VEGFR Unselected
Placebo + paclitaxel 335
Shen L 2015 [9] Bevacizumab + Cisplatin + Capecitabine 100 Asia FL VEGFR Unselected
Placebo + Cisplatin + Capecitabine 102
Lordick F 2013 [10] Cetuximab + Capecitabine + cisplatin 455 worldwide FL EGFR Unselected
Capecitabine + cisplatin 449
Waddell T 2013 [12] Panitumumab +mEOC 278 Europe FL EGFR Unselected
Epirubicin + Capecitabine + oxaliplatin 275
Rao S 2010 [13] matuzumab + Epirubicin + Capecitabine + cisplatin 35 Europe FL EGFR Selected
Epirubicin + Capecitabine + cisplatin 36
NCT01246960 [15] Ramucirumab + Oxaliplatin + Leucovorin + 5-Fu 84 N FL VEGFR Unselected
Placebo + Oxaliplatin + Leucovorin + 5-Fu 84
Ohtsu A 2011 [16] Bevacizumab + fluoropyrimidine + cisplatin 387 worldwide FL VEGFR Unselected
Placebo + fluoropyrimidine-cisplatin 387
Du F 2015 [17] Nimotuzumab + S-1 + Cisplatin 31 Asia FL EGFR Unselected
S-1 + Cisplatin 31
Koizumi W 2013 [18] TSU-68 + S-1 + cisplatin 45 Asia FL VEGFR Unselected
S-1 + cisplatin 46
Satoh T 2015 [19] Nimotuzumab + irinotecan 40 Asia SL EGFR Unselected
Irinotecan 42
Satoh T 2014 [20] lapatinib + paclitaxel 132 Asia SL EGFR Selected
Paclitaxe 129
Yi J. H 2012 [21] Sunitinib + docetaxel 56 Asia SL VEGFR Unselected
Docetaxel 49
Hecht J. R 2016 [22] Lapatinib + Capecitabine + Oxaliplatin 272 worldwide FL EGFR Selected
Placebo + Capecitabine + Oxaliplatin 273
PN patient number, TP treatment plan, TG the targeted gene, FL first-line, SL second-line, Selected the EGFR-positive, unselected the whole patients, N unknown
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effect of combined chemotherapy is limited. Studies
have found that, despite of the development of new
chemotherapy regimens, the 5-year survival of patients
in this setting was less than 10 %, median survival time
was only 10–13 months [23]. In recent years, it is
thought that VEGFR and EGFR play a crucial role in
the growth of most primary tumors and the subsequent
process of metastasis. The expression of VEGFR and
EGFR was an independent prognostic indicator of worse
outcome in gastric cancer patients [24]. EGFR has been
identified widely expressed in a variety of tumors and
about 20 % to 30 % of patients with gastric carcinoma
overexpress EGFR [6]. Therefore, application of EGFR and
VEGFR molecular targeted drugs may provide a new
direction for treatment of advanced gastric cancer. A
study with truastuzumab combined chemotherapy showedfavorable efficacy of a 68 % response rate, 16 months of
OS, and 7.8 months of PFS in EGFR-positive advanced
gastric cancer [25]. In another clinical trial, ramucirumab
(anti-VEGFR target drugs) monopoly chemotherapy re-
sulted significant survival benefit compared with the best
support care [26]. Moreover, the expression of related
genes may affect the therapeutic effect of target combined
chemotherapy for patients with advanced gastric cancer.
The EXPAND trail shown that the selected (EGFR-posi-
tive) patients has better improvement for ORR than the
unselected when treated with target combined chemo-
therapy [10]. The subgroup analysis of AVAGAST trail
shown that target combined chemotherapy has signifi-
cant benefit for OS in the selected (VEGFR-positive)
patients (HR = 0.72; 95 % CI: 0.57 to 0.93) [27] and that
was not noted in unselected patients (HR = 0.87; 95 % CI:
0.73 to 1.03) [16].
Table 2 Quality assessment of RCTs by Cochrane manual
scoring standard
Studies Design RM Blinding Follow-up DT Quality
Bang Y. J 2010 [7] RCT IVR Single Yes Yes A
Wilke H 2014 [8] RCT IVR Double Yes Yes A
Shen L 2015 [9] RCT IVR Double Yes Yes A
Lordick F 2013 [10] RCT IVR Single Yes Yes A
Waddell T 2013 [12] RCT IVR Single Yes Yes A
Rao S 2010 [13] RCT IVR Single Yes Yes A
NCT01246960 [15] RCT N Double Yes Yes B
Ohtsu A 2011 [16] RCT IVR Double Yes Yes A
Du F 2015 [17] RCT IVR Single Yes Yes A
Koizumi W 2013 [18] RCT IVR Single Yes Yes A
Satoh T 2015 [19] RCT RPD Single Yes Yes A
Satoh T 2014 [20] RCT IVR Single Yes Yes A
Yi J. H 2012 [21] RCT IVR Single Yes Yes A
Hecht J. R 2016 [22] RCT IVR Double Yes Yes A
IVR interactive voice recognition system, RPD random permuted blocks,
RM randomization method, DST description of test methods
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pose of assessing the possible benefit in terms of OS,
PFS and ORR by adding anti-EGFR or anti-VEGFR
target drugs to chemotherapy. Overall, we noted that
the target combined chemotherapy arm had significant
improvement for OS and ORR. Therefore, we think the
target combined chemotherapy has better overall survivalFig. 2 Hazard ratio (HR) for progression-free survival (OS) of the included trbenefit and treatment efficiency than the traditional
chemotherapy for patients with unresectable advanced or
recurrence gastric cancer. Regarding to that the two arms
had significant heterogeneity for PFS and ORR (I2 was
68.2 % and 63.8 % respectively) and there were no signifi-
cant improvement for PFS (HR = 0.89, 95 % CI: 0.77–1.00,
P = 0.055) between two arms, we grouped the studies into
three subgroups according to the difference of the drugs
and patient’s status. The PFS and OS were significantly
improved in anti-VEGFR target drugs for unselected pa-
tient subgroup and anti-EGFR target drugs for selected
(EGFR-positive) patient subgroup, but no significant im-
provement was found in anti-EGFR target drugs for unse-
lected patient subgroup. This difference may due to the
different mechanism of anti-EGFR and anti-VEGFR target
drugs and the limited clinical trials in subgroups. It indi-
cated that anti-VEGFR target drugs can prolong the life
time of patients with gastric cancer, but anti-EGFR drugs
can only prolong the life time of the EGFR-positive pa-
tients with advanced gastric cancer. For ORR, The result
showed significantly improved in anti-VEGFR target drugs
for unselected patient subgroup, but no difference in anti-
EGFR target drugs for selected and anti-EGFR target
drugs for unselected patient subgroup. The difference may
be explained by the limited clinical trials (only four trails
were involved in this subgroup), and the result in anti-
EGFR target drugs for selected patients subgroup is greatly
influenced by the data by Rao et al. (OR = 0.33, 95 % CI:
0.12–0.87) [13]. When we omitted the data by Rao et al.,ials
Fig. 3 Hazard ratio (HR) for overall survival (OS) of the included trials
Fig. 4 Odds ratio (OR) for overall response rate (ORR) of the included studies. Abbreviations:hazard ratio (HR); 95 % confidence interval (95 % CI);
anti epidermal growth factor receptor target drugs for selected patients subgroup (EGFR/selected); anti vascular endothelial growth factor
receptor target drugs for unselected patients subgroup (EGFR/unselected); anti epidermal growth factor receptor target drugs for unselected
patients subgroup (VEGFR/unselected)
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Table 3 Grade 3 to 4 adverse events of interest
AEs I2 OR 95 % CI P value
Anemia 0.0 % 1.02 0.83–1.24 0.883
Thrombocytopenia 39.2 % 1.06 0.74–1.51 0.771
Leucopenia 66.1 % 1.24 0.73–2.10 0.433
Neutropenia 85.8 % 1.33 0.88–2.01 0.179
Febrile neutropenia 67.2 % 1.34 0.68–2.67 0.401
Hypokalemia 38.1 % 1.09 0.81–1.47 0.586
Rash 0.0 % 21.84 6.81–70.02 <0.001*
Hand-foot syndrome 37.6 % 1.75 1.22–2.50 0.002*
Stomatitis 42.8 % 2.08 1.23–3.51 0.006*
Nausea 21.6 % 0.94 0.73–1.21 0.639
Vomit 0.3 % 0.99 0.79–1.25 0.944
Abdominal pain 0.0 % 1.10 0.47–2.57 0.821
Diarrhea 14.1 % 2.40 1.88–3.06 <0.001*
Constipation 0.0 % 0.27 0.08–0.91 0.034*
Decreased appetite 0.0 % 1.13 0.88–1.46 0.342
Fatigue 0.0 % 1.55 1.21–2.00 0.001*
Neuropathy 62.8 % 0.76 0.24–2.41 0.636
Any adverse events 86.8 % 1.53 0.98–2.40 0.062
*P < 0.005, There were statistically significant differences between the two arms
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EGFR target drugs for selected patient subgroup (OR =
1.46, 95 % CI: 1.27–1.67). That the different result was
greatly influenced by the data by Rao et al. was also found
in another meta-analysis [28].
For grade 3–4 adverse events, we noted that the target
combined chemotherapy arm had an obviously increased
incidence of the skin and subcutaneous tissue disorders
and diarrhea. This was also found in another meta-
analysis [28] and some other clinic trails [10, 29, 30].
The skin and subcutaneous tissue disorders may be the
special adverse events for the target drugs and we may
need to prevent its occurrence when using target drugs.
There was no significant difference in the incidence of
grade 3–4 blood and lymphatic system adverse events of
the two groups, and it means the safety of the blood sys-
tem of target combined chemotherapy arm is equivalent
to chemotherapy alone arm. For all of the outcomes, the
large-scale multicenter randomized clinical trials are still
needed.
Our meta-analysis has some limitations. Firstly, the
meta-analysis used the pooled data which came from
published papers, not original data. Secondly, there were
several target drugs in this meta-analysis, and the basic
chemotherapy, treatment strategy and duration were also
different. These all contribute to the high heterogeneity of
this meta-analysis. Thirdly, as demonstrated in some trails
[19, 22, 31], the improvement of patients from different
regions is distinct. The sub-analysis in RAINBOW andToGA trails demonstrated different improvement in OS
between Asian and the whole patients, and the HR for
Asian patients was 0.99 (95 % CI: 0.73–1.34) [31] and 0.82
(95 % CI,: 0.61 to 1.11) [11] respectively, however, there
were significant improvement in OS in the whole patients.
In this meta-analysis, we do not consider the effect of re-
gional differences on the results. Moreover, as shown in
AVAGAST trail, the OS benefit was achieved in the se-
lected but not the whole patients, it is possible that the
significant improved efficacy of anti-VEGFR target drugs
may be justly achieved by refining the selection of the pa-
tient population [16]. Little studies were designed for the
VEGFR-positive patients with advanced gastric cancer. At
the same time, there is little literature to provide quality
of life and the cost of treatment between the two arms,
so this meta-analysis did not carry out the relative
conclusion.
In conclusion, this meta-analysis indicated the target
combined chemotherapy was associated with significant
improvement for OS and ORR compared with trad-
itional chemotherapy. The addition of anti-VEGFR target
drugs to chemotherapy for gastric cancer significantly
improved outcome of OS, PFS, ORR, while anti-EGFR
target drugs only led to improved outcome for OS and
PFS in EGFR-positive gastric cancer. Some adverse events
were increased in target combined chemotherapy arm.
We recommended anti-VEGFR target drugs can be used
for the whole patients with gastric cancer, and anti-EGFR
drugs should be selected to EGFR-positive patients. Mean-
while, more high-quality randomized controlled trials are
needed to provide more information. And whether the
efficacy of anti-VEGFR target drugs is justly achieved
by refining the selection of the patient population or
not need further research.Conclusions
Generally speaking, the target combined chemotherapy
represented a better overall survival benefit and treat-
ment efficiency and higher incidence of some grade 3–4
adverse events than the traditional chemotherapy for pa-
tients with unresectable advanced or recurrence gastric
cancer. The anti-VEGFR drugs can improve the efficacy
for the whole patients with unresectable advanced or re-
currence gastric cancer and the anti-EGFR drugs can only
improve the efficacy for the EGFR-positive patients.
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